GangaGen Garners $5,400,000 Series E Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    6167Jarvis Ave. No.324 Newark Palo Alto, CA 94560
  • Company Description
    GangaGen, Inc. is a biotechnology company focused on the development of proprietary, bacteriophage-based products for the prevention and treatment of bacterial infections, particularly infections that are resistant to antibiotics, through the application of contemporary molecular and clinical sciences. The Company’s bacteriophage, both natural and engineered, can be applied broadly to kill bacteria pathogenic to humans.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series E
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Atel Ventures, Inc.
  • Venture Investor

Trending on Xconomy